Literature DB >> 19170164

Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients.

Maria Juliana Majado1, Alfredo Minguela, Consuelo González-García, Eduardo Salido, Miguel Blanquer, Consuelo Funes, Carmen Luisa Insausti, Ana María García-Hernández, José María Moraleda, Alfonso Morales.   

Abstract

Given that pre-apheresis CD34(+) cell count (PA-CD34) predicts the apheresis' yield, a minimum of 5 to 20 PA-CD34/microl is required in many institutions to initiate cell collection. The aim of this study was to clarify whether large-volume-apheresis (LVA) could facilitate progenitor cell transplantation in patients with low PA-CD34. Apheresis was initiated in 226 patients, disregarding PA-CD34, at days: +5 in G-CSF, +10 in cyclophosphamide+G-CSF, and +15 to +20 in other chemotherapy+G-CSF mobilization, when leucocytes >2.5 x 10(9)/L. Four times the blood volume was processed. Patients were grouped according to their PA-CD34: >or=10/microl (group-A, n = 143); <10/microl but >or=5/microl (group-B, n = 40) and <5/microl (group-C, n = 43). No differences were found in diagnoses, gender, age, previous treatments or mobilization regimen between groups. Enough CD34(+) cells (>1.9 x 10(6)/kg) were obtained in 31 patients (72%) from group-C, although in this group two mobilizations were needed in 20 patients (46.5%), compared to 5 (3.5%) and 1 (2.5%) in groups A and B, respectively (P < 0.01). Evenly three apheresis or more were required in 28 patients (65.1%) from group-C, compared to 8 (5.6%) and 6 (15.0%) in groups A and B, respectively (P < 0.01). In conclusion LVA can facilitate autologous transplantation in poor-mobilizer-patients, low PA-CD34 should not be an inflexible exclusion factor. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19170164     DOI: 10.1002/jca.20191

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  4 in total

1.  Turning CD34 Non-Mobilizers into Mobilizers: A Case Report Involving Plerixafor (AMD3100).

Authors:  Henk S P Garritsen; Thomas Gabrysiak; Andreas Sputtek; Bettina Biermann; Bernhard Wörmann
Journal:  Transfus Med Hemother       Date:  2009-09-10       Impact factor: 3.747

2.  Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.

Authors:  Andreas Humpe; Ute Buwitt-Beckmann; Natalie Schub; Martin Gramatzki; Andreas Günther
Journal:  Transfus Med Hemother       Date:  2013-07-25       Impact factor: 3.747

3.  Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo.

Authors:  A Olivieri; M Marchetti; R Lemoli; C Tarella; A Iacone; F Lanza; A Rambaldi; A Bosi
Journal:  Bone Marrow Transplant       Date:  2011-05-30       Impact factor: 5.483

Review 4.  Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.

Authors:  Saeed Mohammadi; Ashraf Malek Mohammadi; Mohsen Nikbakht; Amir Hossein Norooznezhad; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-01-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.